SNY Jan 2025 38.000 put
| Previous close | 0.0900 |
| Open | 0.0900 |
| Bid | 0.0500 |
| Ask | 1.2500 |
| Strike | 38.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0900 - 0.0900 |
| Contract range | N/A |
| Volume | |
| Open interest | 395 |
Investor's Business DailyNovavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
Novavax stock remains volatile. After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back.
BloombergSanofi’s Hudson Nears Goal of Splitting Off Consumer Health Unit
(Bloomberg) -- Sanofi is nearing the sale of its consumer health business to Clayton Dubilier & Rice, a year after Chief Executive Officer Paul Hudson announced plans to split off the division to concentrate on developing innovative medicines.Most Read from BloombergThe Cablebus Transformed Commutes in Mexico City’s Populous OutskirtsSan Francisco to Shut 9% of Public Schools Amid Budget WoesAs Brussels Booms, an Old Boogeyman Returns: BrusselizationChicago Marathon to Honor Kenyan Who Died Afte
ReutersSanofi in talks to sell 50% stake in consumer health business to CD&R
PARIS (Reuters) -Sanofi has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice, the French pharmaceutical group said on Friday. The announcement confirms an earlier Reuters report that it was closing in on a sale estimated at around 15 billion euros ($16.41 billion). Sanofi did not disclose any financial details of the potential deal, and said further updates would be provided in due course.
